Nevertheless, the superiority of alectinib over crizotinib was evident, hence in November 2017, the FDA approved alectinib for the first-line treatment of patients with advanced ALK-positive NSCLC, at a recommended dose of 600 mg orally twice per day with food. This evidence concerns the gene ALK and non-small cell lung carcinoma.